Kilpest India Limited
Kilpest India Limited (KILPEST.BO) Stock Competitors & Peer Comparison
See (KILPEST.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KILPEST.BO | ₹808.55 | +2.41% | 6.3B | 18.32 | ₹44.14 | N/A |
| BIOCON.NS | ₹362.25 | +0.07% | 460.5B | 74.19 | ₹4.89 | +0.14% |
| BIOCON.BO | ₹362.30 | +0.14% | 460.5B | 74.34 | ₹4.88 | +0.14% |
| ANTHEM.NS | ₹775.25 | +0.71% | 434.9B | 90.24 | ₹8.58 | N/A |
| PPLPHARMA.NS | ₹160.15 | -5.11% | 217.7B | -133.72 | -₹1.23 | +0.09% |
| ONESOURCE.NS | ₹1,762.50 | -3.76% | 202.1B | 963.39 | ₹1.83 | N/A |
| SYNGENE.NS | ₹432.15 | -1.32% | 176.9B | 50.26 | ₹8.76 | +0.28% |
| SYNGENE.BO | ₹432.30 | -1.28% | 176.8B | 50.23 | ₹8.76 | +0.28% |
| JUBLINGREA.NS | ₹702.75 | -4.34% | 113.6B | 43.00 | ₹16.75 | +0.69% |
| CONCORDBIO.NS | ₹1,134.50 | +7.24% | 112.1B | 36.01 | ₹29.77 | +1.00% |
Stock Comparison
KILPEST.BO vs BIOCON.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, BIOCON.NS has a market cap of 460.5B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while BIOCON.NS trades at ₹362.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas BIOCON.NS's P/E ratio is 74.19. In terms of profitability, KILPEST.BO's ROE is N/A, compared to BIOCON.NS's ROE of +0.02%. Regarding short-term risk, KILPEST.BO is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check BIOCON.NS's competition here
KILPEST.BO vs BIOCON.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, BIOCON.BO has a market cap of 460.5B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while BIOCON.BO trades at ₹362.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas BIOCON.BO's P/E ratio is 74.34. In terms of profitability, KILPEST.BO's ROE is N/A, compared to BIOCON.BO's ROE of +0.02%. Regarding short-term risk, KILPEST.BO is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check BIOCON.BO's competition here
KILPEST.BO vs ANTHEM.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, ANTHEM.NS has a market cap of 434.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while ANTHEM.NS trades at ₹775.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas ANTHEM.NS's P/E ratio is 90.24. In terms of profitability, KILPEST.BO's ROE is N/A, compared to ANTHEM.NS's ROE of +0.19%. Regarding short-term risk, KILPEST.BO is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check ANTHEM.NS's competition here
KILPEST.BO vs PPLPHARMA.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, PPLPHARMA.NS has a market cap of 217.7B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while PPLPHARMA.NS trades at ₹160.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas PPLPHARMA.NS's P/E ratio is -133.72. In terms of profitability, KILPEST.BO's ROE is N/A, compared to PPLPHARMA.NS's ROE of -0.02%. Regarding short-term risk, KILPEST.BO is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check PPLPHARMA.NS's competition here
KILPEST.BO vs ONESOURCE.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, ONESOURCE.NS has a market cap of 202.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while ONESOURCE.NS trades at ₹1,762.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas ONESOURCE.NS's P/E ratio is 963.39. In terms of profitability, KILPEST.BO's ROE is N/A, compared to ONESOURCE.NS's ROE of +0.00%. Regarding short-term risk, KILPEST.BO is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check ONESOURCE.NS's competition here
KILPEST.BO vs SYNGENE.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SYNGENE.NS has a market cap of 176.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SYNGENE.NS trades at ₹432.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SYNGENE.NS's P/E ratio is 50.26. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, KILPEST.BO is less volatile compared to SYNGENE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check SYNGENE.NS's competition here
KILPEST.BO vs SYNGENE.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SYNGENE.BO has a market cap of 176.8B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SYNGENE.BO trades at ₹432.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SYNGENE.BO's P/E ratio is 50.23. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, KILPEST.BO is less volatile compared to SYNGENE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check SYNGENE.BO's competition here
KILPEST.BO vs JUBLINGREA.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, JUBLINGREA.NS has a market cap of 113.6B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while JUBLINGREA.NS trades at ₹702.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas JUBLINGREA.NS's P/E ratio is 43.00. In terms of profitability, KILPEST.BO's ROE is N/A, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, KILPEST.BO is less volatile compared to JUBLINGREA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check JUBLINGREA.NS's competition here
KILPEST.BO vs CONCORDBIO.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, CONCORDBIO.NS has a market cap of 112.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while CONCORDBIO.NS trades at ₹1,134.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas CONCORDBIO.NS's P/E ratio is 36.01. In terms of profitability, KILPEST.BO's ROE is N/A, compared to CONCORDBIO.NS's ROE of +0.18%. Regarding short-term risk, KILPEST.BO is less volatile compared to CONCORDBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check CONCORDBIO.NS's competition here
KILPEST.BO vs CONCORDBIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, CONCORDBIO.BO has a market cap of 112B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while CONCORDBIO.BO trades at ₹1,131.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas CONCORDBIO.BO's P/E ratio is 35.99. In terms of profitability, KILPEST.BO's ROE is N/A, compared to CONCORDBIO.BO's ROE of +0.18%. Regarding short-term risk, KILPEST.BO is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check CONCORDBIO.BO's competition here
KILPEST.BO vs BLUEJET.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, BLUEJET.NS has a market cap of 76.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while BLUEJET.NS trades at ₹445.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas BLUEJET.NS's P/E ratio is 26.24. In terms of profitability, KILPEST.BO's ROE is N/A, compared to BLUEJET.NS's ROE of +0.26%. Regarding short-term risk, KILPEST.BO is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check BLUEJET.NS's competition here
KILPEST.BO vs BLUEJET.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, BLUEJET.BO has a market cap of 76.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while BLUEJET.BO trades at ₹445.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas BLUEJET.BO's P/E ratio is 26.22. In terms of profitability, KILPEST.BO's ROE is N/A, compared to BLUEJET.BO's ROE of +0.26%. Regarding short-term risk, KILPEST.BO is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check BLUEJET.BO's competition here
KILPEST.BO vs SUPRIYA.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SUPRIYA.NS has a market cap of 56.7B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SUPRIYA.NS trades at ₹698.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SUPRIYA.NS's P/E ratio is 30.63. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SUPRIYA.NS's ROE of +0.19%. Regarding short-term risk, KILPEST.BO is more volatile compared to SUPRIYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check SUPRIYA.NS's competition here
KILPEST.BO vs SUPRIYA.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SUPRIYA.BO has a market cap of 56.7B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SUPRIYA.BO trades at ₹698.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SUPRIYA.BO's P/E ratio is 30.54. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SUPRIYA.BO's ROE of +0.19%. Regarding short-term risk, KILPEST.BO is more volatile compared to SUPRIYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check SUPRIYA.BO's competition here
KILPEST.BO vs ZOTA.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, ZOTA.NS has a market cap of 39.5B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while ZOTA.NS trades at ₹1,312.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas ZOTA.NS's P/E ratio is -54.23. In terms of profitability, KILPEST.BO's ROE is N/A, compared to ZOTA.NS's ROE of -0.31%. Regarding short-term risk, KILPEST.BO is less volatile compared to ZOTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check ZOTA.NS's competition here
KILPEST.BO vs DCAL.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, DCAL.NS has a market cap of 28.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while DCAL.NS trades at ₹181.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas DCAL.NS's P/E ratio is 24.33. In terms of profitability, KILPEST.BO's ROE is N/A, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, KILPEST.BO is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check DCAL.NS's competition here
KILPEST.BO vs DCAL.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, DCAL.BO has a market cap of 28.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while DCAL.BO trades at ₹181.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas DCAL.BO's P/E ratio is 24.29. In terms of profitability, KILPEST.BO's ROE is N/A, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, KILPEST.BO is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check DCAL.BO's competition here
KILPEST.BO vs PANACEABIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, PANACEABIO.BO has a market cap of 23.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while PANACEABIO.BO trades at ₹369.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas PANACEABIO.BO's P/E ratio is -292.52. In terms of profitability, KILPEST.BO's ROE is N/A, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, KILPEST.BO is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check PANACEABIO.BO's competition here
KILPEST.BO vs PANACEABIO.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, PANACEABIO.NS has a market cap of 23.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while PANACEABIO.NS trades at ₹370.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas PANACEABIO.NS's P/E ratio is -292.25. In terms of profitability, KILPEST.BO's ROE is N/A, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, KILPEST.BO is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check PANACEABIO.NS's competition here
KILPEST.BO vs TITANBIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, TITANBIO.BO has a market cap of 18.7B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while TITANBIO.BO trades at ₹474.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas TITANBIO.BO's P/E ratio is 68.58. In terms of profitability, KILPEST.BO's ROE is N/A, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, KILPEST.BO is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check TITANBIO.BO's competition here
KILPEST.BO vs 3BBLACKBIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, 3BBLACKBIO.BO has a market cap of 11.2B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while 3BBLACKBIO.BO trades at ₹1,267.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas 3BBLACKBIO.BO's P/E ratio is 19.70. In terms of profitability, KILPEST.BO's ROE is N/A, compared to 3BBLACKBIO.BO's ROE of +0.00%. Regarding short-term risk, KILPEST.BO is less volatile compared to 3BBLACKBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check 3BBLACKBIO.BO's competition here
KILPEST.BO vs FERMENTA.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, FERMENTA.BO has a market cap of 9.2B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while FERMENTA.BO trades at ₹312.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas FERMENTA.BO's P/E ratio is 10.55. In terms of profitability, KILPEST.BO's ROE is N/A, compared to FERMENTA.BO's ROE of +0.25%. Regarding short-term risk, KILPEST.BO is more volatile compared to FERMENTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check FERMENTA.BO's competition here
KILPEST.BO vs TAKE.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, TAKE.NS has a market cap of 6.6B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while TAKE.NS trades at ₹43.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas TAKE.NS's P/E ratio is -444.40. In terms of profitability, KILPEST.BO's ROE is N/A, compared to TAKE.NS's ROE of +0.12%. Regarding short-term risk, KILPEST.BO is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check TAKE.NS's competition here
KILPEST.BO vs TAKE.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, TAKE.BO has a market cap of 6.5B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while TAKE.BO trades at ₹43.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas TAKE.BO's P/E ratio is -442.20. In terms of profitability, KILPEST.BO's ROE is N/A, compared to TAKE.BO's ROE of +0.12%. Regarding short-term risk, KILPEST.BO is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check TAKE.BO's competition here
KILPEST.BO vs HALEOSLABS.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, HALEOSLABS.NS has a market cap of 4.3B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while HALEOSLABS.NS trades at ₹1,500.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas HALEOSLABS.NS's P/E ratio is 21.91. In terms of profitability, KILPEST.BO's ROE is N/A, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, KILPEST.BO is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check HALEOSLABS.NS's competition here
KILPEST.BO vs HALEOSLABS.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, HALEOSLABS.BO has a market cap of 4.3B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while HALEOSLABS.BO trades at ₹1,480.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas HALEOSLABS.BO's P/E ratio is 21.75. In terms of profitability, KILPEST.BO's ROE is N/A, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, KILPEST.BO is less volatile compared to HALEOSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check HALEOSLABS.BO's competition here
KILPEST.BO vs SMSLIFE.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SMSLIFE.BO has a market cap of 4.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SMSLIFE.BO trades at ₹1,480.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SMSLIFE.BO's P/E ratio is 22.15. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SMSLIFE.BO's ROE of +0.10%. Regarding short-term risk, KILPEST.BO is less volatile compared to SMSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check SMSLIFE.BO's competition here
KILPEST.BO vs SMSLIFE.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, KILPEST.BO is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check SMSLIFE.NS's competition here
KILPEST.BO vs LYKALABS.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, LYKALABS.BO has a market cap of 2.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while LYKALABS.BO trades at ₹61.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas LYKALABS.BO's P/E ratio is 101.78. In terms of profitability, KILPEST.BO's ROE is N/A, compared to LYKALABS.BO's ROE of -0.01%. Regarding short-term risk, KILPEST.BO is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check LYKALABS.BO's competition here
KILPEST.BO vs LYKALABS.NS Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, LYKALABS.NS has a market cap of 2.1B. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while LYKALABS.NS trades at ₹60.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas LYKALABS.NS's P/E ratio is -349.29. In terms of profitability, KILPEST.BO's ROE is N/A, compared to LYKALABS.NS's ROE of -0.01%. Regarding short-term risk, KILPEST.BO is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check LYKALABS.NS's competition here
KILPEST.BO vs ALFAVIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, ALFAVIO.BO has a market cap of 480.8M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while ALFAVIO.BO trades at ₹14.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas ALFAVIO.BO's P/E ratio is -508.33. In terms of profitability, KILPEST.BO's ROE is N/A, compared to ALFAVIO.BO's ROE of -0.00%. Regarding short-term risk, KILPEST.BO is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check ALFAVIO.BO's competition here
KILPEST.BO vs SAMSRITA.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SAMSRITA.BO has a market cap of 254.7M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SAMSRITA.BO trades at ₹16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SAMSRITA.BO's P/E ratio is -4.31. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SAMSRITA.BO's ROE of -0.61%. Regarding short-term risk, KILPEST.BO is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check SAMSRITA.BO's competition here
KILPEST.BO vs TRABI.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, TRABI.BO has a market cap of 218.2M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while TRABI.BO trades at ₹2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas TRABI.BO's P/E ratio is -11.52. In terms of profitability, KILPEST.BO's ROE is N/A, compared to TRABI.BO's ROE of -0.19%. Regarding short-term risk, KILPEST.BO is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check TRABI.BO's competition here
KILPEST.BO vs STARSOURCE.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, STARSOURCE.BO has a market cap of 177.8M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while STARSOURCE.BO trades at ₹123.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas STARSOURCE.BO's P/E ratio is -1.47. In terms of profitability, KILPEST.BO's ROE is N/A, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, KILPEST.BO is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check STARSOURCE.BO's competition here
KILPEST.BO vs VANTABIO.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, VANTABIO.BO has a market cap of 115.6M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while VANTABIO.BO trades at ₹16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas VANTABIO.BO's P/E ratio is -2.38. In terms of profitability, KILPEST.BO's ROE is N/A, compared to VANTABIO.BO's ROE of -0.34%. Regarding short-term risk, KILPEST.BO is more volatile compared to VANTABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KILPEST.BO.Check VANTABIO.BO's competition here
KILPEST.BO vs GVBL.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, GVBL.BO has a market cap of 74.1M. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while GVBL.BO trades at ₹24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas GVBL.BO's P/E ratio is -220.45. In terms of profitability, KILPEST.BO's ROE is N/A, compared to GVBL.BO's ROE of +0.03%. Regarding short-term risk, KILPEST.BO is less volatile compared to GVBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check GVBL.BO's competition here
KILPEST.BO vs SERVOTEACH.BO Comparison April 2026
KILPEST.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KILPEST.BO stands at 6.3B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, KILPEST.BO is priced at ₹808.55, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KILPEST.BO currently has a P/E ratio of 18.32, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, KILPEST.BO's ROE is N/A, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, KILPEST.BO is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KILPEST.BO.Check SERVOTEACH.BO's competition here